Free tool
FAERS Monitor: Clinimix E 5/20 Sulfite Free W/ Elect In 20% Dextrose W/ Calcium In Plastic Container
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020678 or its brand name (Clinimix E 5/20 Sulfite Free W/ Elect In 20% Dextrose W/ Calcium In Plastic Container, Amino Acids, Calcium Chloride, Dextrose, Magnesium Chloride, Potassium Phosphate, Dibasic, Sodium Acetate, Sodium Chloride). Reports on generic versions are filed under their own applications.
Reports
79
Serious
47
59% of reports
Hospitalization
19
Death reported
11
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event10
- wrong technique in drug usage process9
- dyspnoea6
- nausea6
- death5
- headache4
- poor quality drug administered4
- urticaria4
- asthenia3
- blood creatinine increased3
- blood potassium increased3
- erythema3
- extravasation3
- fungaemia3
- general physical health deterioration3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2013 | 2 |
| 2014 | 7 |
| 2015 | 9 |
| 2016 | 7 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 11 |
| 2021 | 9 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 9 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,080 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fungaemiaSignal | 3 | 508.6 | 167.4 | 1,053 |
| extravasationSignal | 3 | 194.5 | 64.1 | 400 |
| poor quality drug administeredSignal | 4 | 164.6 | 63.3 | 497 |
| wrong technique in drug usage processSignal | 9 | 66.0 | 35.7 | 513 |
| blood potassium increasedSignal | 3 | 49.2 | 16.2 | 98 |
| no adverse eventSignal | 10 | 14.7 | 8.2 | 115 |
| blood creatinine increasedSignal | 3 | 12.2 | 4.0 | 21 |
| general physical health deteriorationSignal | 3 | 6.9 | 2.3 | 10 |
| urticariaSignal | 4 | 6.4 | 2.4 | 13 |
| erythema | 3 | 3.9 | 1.3 | 4 |
| dyspnoeaSignal | 6 | 2.8 | 1.3 | 6 |
| asthenia | 3 | 2.1 | 0.7 | 1 |
| nausea | 6 | 2.0 | 0.9 | 2 |
| headache | 4 | 1.7 | 0.7 | 1 |
| death | 5 | 1.5 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.